(Q35050634)

English

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jonathan Chernoff

object named as

Jonathan Chernoff

8

0 references

author name string

Igor Makhlin

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jiaru Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Christopher J Long

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Karthik Devarajan

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Yan Zhou

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Andres J Klein-Szanto

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Min Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Stephen A Boorjian

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

2 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

108

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2 Pt 2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

E84-90

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Targeting the mTOR signaling network for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Inactivation of p53 and Pten promotes invasive bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Effect of sirolimus on urinary bladder cancer T24 cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Defining the role of mTOR in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Defining optimal therapy for muscle invasive bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

8 July 2018

Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09844.X

21 January 2018

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09844.X

21 January 2018

The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

25 October 2018

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116980

25 October 2018

Activation of the mTOR signaling pathway in renal clear cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21050361

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1464-410X.2010.09844.X

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35050634&oldid=1567703402"